Scilex Holding (SCLX) EPS (Basic) (QoQ) (2020 - 2026)
Scilex Holding (SCLX) EPS (Basic) (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.52% |
| Dec 31, 2025 | 79.25% |
| Sep 30, 2025 | -198.79% |
| Jun 30, 2025 | -228.32% |
| Mar 31, 2025 | -140.87% |
| Dec 31, 2024 | 1,053.45% |
| Sep 30, 2024 | 92.44% |
| Jun 30, 2024 | 7.92% |
| Mar 31, 2024 | -3,232.00% |
| Dec 31, 2023 | 60.32% |
| Sep 30, 2023 | -231.58% |
| Jun 30, 2023 | 13.64% |
| Mar 31, 2023 | -69.23% |
| Dec 31, 2022 | -181.25% |
| Sep 30, 2022 | 223.08% |
| Jun 30, 2022 | -85.71% |
| Mar 31, 2022 | 89.23% |
| Dec 31, 2021 | -712.50% |
| Sep 30, 2021 | -700.00% |
| Jun 30, 2021 | -111.11% |